{"log_id": 9069123054776367535, "direction": 0, "words_result_num": 49, "words_result": [{"probability": {"variance": 0.000216, "average": 0.990456, "min": 0.963057}, "location": {"width": 164, "top": 171, "height": 28, "left": 181}, "words": "常一血液学部分)"}, {"probability": {"variance": 2e-06, "average": 0.999252, "min": 0.996264}, "location": {"width": 147, "top": 198, "height": 26, "left": 222}, "words": "实验室结果异常"}, {"probability": {"variance": 0.011331, "average": 0.968298, "min": 0.443299}, "location": {"width": 788, "top": 210, "height": 44, "left": 222}, "words": "血液学:罗格列酮可致患者的平均面红蛋白和红细胞积下降,且与剂量相关(个别试"}, {"probability": {"variance": 0.011026, "average": 0.969639, "min": 0.38459}, "location": {"width": 808, "top": 239, "height": 43, "left": 182}, "words": "验中,平均血红蛋白和红细胞积的减少可分别达到1g和3.3%)。单用罗格列酮或与"}, {"probability": {"variance": 0.000682, "average": 0.987425, "min": 0.873352}, "location": {"width": 825, "top": 266, "height": 44, "left": 184}, "words": "甲双胍/磺酰脲类药物合用时,血液学指标改变的时间和程度是相似的。罗格列酮与二甲双"}, {"probability": {"variance": 0.009862, "average": 0.975668, "min": 0.379058}, "location": {"width": 829, "top": 295, "height": 43, "left": 181}, "words": "胍合用组患者贫血的发生率较高,可能与罗格列酮治疗前者血红蛋白和血球压积水平较低"}, {"probability": {"variance": 0.003239, "average": 0.981485, "min": 0.718881}, "location": {"width": 828, "top": 322, "height": 44, "left": 183}, "words": "有关。罗格列酮亦可致白细胞计数轻度下降。血液学指标降低可能与罗格列酮可增加血容量"}, {"probability": {"variance": 0, "average": 0.999806, "min": 0.999729}, "location": {"width": 44, "top": 368, "height": 24, "left": 185}, "words": "有关"}, {"probability": {"variance": 1.9e-05, "average": 0.997221, "min": 0.984302}, "location": {"width": 585, "top": 380, "height": 40, "left": 223}, "words": "血脂:罗格列酮可使患者血脂指标发生改变(见临床作用部分)"}, {"probability": {"variance": 0.00209, "average": 0.990029, "min": 0.705659}, "location": {"width": 781, "top": 404, "height": 45, "left": 227}, "words": "血清转氨酶:在多项临床试验中,共有4598例患者接受本品治疗,服用时间约为360"}, {"probability": {"variance": 0.004089, "average": 0.97837, "min": 0.660164}, "location": {"width": 668, "top": 435, "height": 42, "left": 184}, "words": "病人年,无证据表明有药物所致的肝毒性反应或谷丙转氨悔水平升高发生"}, {"probability": {"variance": 0.000235, "average": 0.995451, "min": 0.907158}, "location": {"width": 787, "top": 460, "height": 42, "left": 227}, "words": "在安慰剂或阳性药物对照试验中,谷丙转氨酶水平超过正常上限的3倍的可逆性升高发"}, {"probability": {"variance": 0.005136, "average": 0.980541, "min": 0.579458}, "location": {"width": 829, "top": 488, "height": 44, "left": 185}, "words": "生率分别为:罗格列酮组0.2%,安慰剂组0.2%,阳性对照组0.5%高胆红素血症的发生率"}, {"probability": {"variance": 0.000137, "average": 0.993816, "min": 0.943048}, "location": {"width": 535, "top": 520, "height": 41, "left": 184}, "words": "分别为:罗格列酮组0.3%,安慰剂组0.9%,阳性对照组1%"}, {"probability": {"variance": 0.006521, "average": 0.981937, "min": 0.505879}, "location": {"width": 788, "top": 543, "height": 44, "left": 227}, "words": "在长期开放的临床试验中,谷丙转氨酶的升高超过正常上限的3倍的发生率分别为;罗"}, {"probability": {"variance": 0.002403, "average": 0.983184, "min": 0.727872}, "location": {"width": 829, "top": 572, "height": 43, "left": 185}, "words": "格列酮组0.35/100病人年,安慰剂组为0.59/100病人年,阳性药物对照组为0.78/100病"}, {"probability": {"variance": 9e-06, "average": 0.996393, "min": 0.993436}, "location": {"width": 40, "top": 617, "height": 26, "left": 188}, "words": "人年"}, {"probability": {"variance": 0.01698, "average": 0.95455, "min": 0.40903}, "location": {"width": 787, "top": 628, "height": 43, "left": 228}, "words": "罗格列削上市前的临床试验中,无一例特发性药物反应性功能衰竭(详见注意事项章"}, {"probability": {"variance": 1e-06, "average": 0.997557, "min": 0.996507}, "location": {"width": 34, "top": 678, "height": 20, "left": 192}, "words": "节)"}, {"probability": {"variance": 0, "average": 0.999773, "min": 0.999274}, "location": {"width": 73, "top": 705, "height": 29, "left": 194}, "words": "【禁忌】"}, {"probability": {"variance": 0.000362, "average": 0.992343, "min": 0.917144}, "location": {"width": 374, "top": 727, "height": 36, "left": 263}, "words": "对罗格列酮过敏者、肝肾功能不全者禁用"}, {"probability": {"variance": 0.000199, "average": 0.993899, "min": 0.938291}, "location": {"width": 411, "top": 758, "height": 38, "left": 227}, "words": "2.有心衰病史或有心衰危险因素的患者禁用"}, {"probability": {"variance": 0.004841, "average": 0.979279, "min": 0.653539}, "location": {"width": 514, "top": 787, "height": 40, "left": 229}, "words": "3.有心脏病病史,尤其是缺血性心脏病病史的患者禁用"}, {"probability": {"variance": 4.2e-05, "average": 0.996433, "min": 0.972776}, "location": {"width": 460, "top": 819, "height": 37, "left": 261}, "words": "骨质疏松症或发生过非外伤性骨折病史的患者禁用"}, {"probability": {"variance": 1.4e-05, "average": 0.997589, "min": 0.987208}, "location": {"width": 233, "top": 855, "height": 31, "left": 265}, "words": "严重血脂紊乱的患者禁用"}, {"probability": {"variance": 0.025628, "average": 0.928493, "min": 0.42818}, "location": {"width": 789, "top": 904, "height": 41, "left": 229}, "words": "鉴于罗格列酮仅在胰岛素存在的条件下才可发你用查品不用于1型糖尿病或糖"}, {"probability": {"variance": 7.5e-05, "average": 0.994565, "min": 0.970367}, "location": {"width": 186, "top": 946, "height": 30, "left": 190}, "words": "尿病酮症酸中毒患者"}, {"probability": {"variance": 0.020166, "average": 0.939852, "min": 0.429878}, "location": {"width": 788, "top": 955, "height": 54, "left": 231}, "words": "本品与胰岛素或其它口服降糖药合用时,容发生低糖的危险必要时可减少合用"}, {"probability": {"variance": 0.013365, "average": 0.926006, "min": 0.696769}, "location": {"width": 94, "top": 1004, "height": 25, "left": 197}, "words": "药物的剂量"}, {"probability": {"variance": 0.033046, "average": 0.887366, "min": 0.437098}, "location": {"width": 794, "top": 1013, "height": 45, "left": 229}, "words": "排卵:本品同其它噻唑烷酮类药物一样,割便伴有抵捷的绝经前期和无排卵型"}, {"probability": {"variance": 0.016673, "average": 0.951946, "min": 0.417177}, "location": {"width": 752, "top": 1043, "height": 43, "left": 193}, "words": "妇女恢复排卵。随着胰岛素敏感性改善。女性患如不注意避则有妊娠的可能"}, {"probability": {"variance": 0.004131, "average": 0.975904, "min": 0.618571}, "location": {"width": 794, "top": 1067, "height": 47, "left": 231}, "words": "虽然临床前研究发现本品可致激素水平失调(见致癌性、致突变性和对生育力的影响"}, {"probability": {"variance": 0.022697, "average": 0.81032, "min": 0.62897}, "location": {"width": 136, "top": 1035, "height": 84, "left": 1016}, "words": "业股份"}, {"probability": {"variance": 0.016014, "average": 0.955301, "min": 0.424802}, "location": {"width": 781, "top": 1097, "height": 43, "left": 194}, "words": "节),但此改变的临床意义尚不清楚。旦出现月经紊配衡是否继续使用本品"}, {"probability": {"variance": 0.000608, "average": 0.991752, "min": 0.874473}, "location": {"width": 787, "top": 1124, "height": 42, "left": 232}, "words": "血液学:罗格列酮单药治疗或与二甲双胍合用对照临床试验中,可见血红蛋白和红细胞"}, {"probability": {"variance": 0.006302, "average": 0.965834, "min": 0.613653}, "location": {"width": 829, "top": 1152, "height": 42, "left": 191}, "words": "压积下降(个别试验中,平均血红蛋白和血球玉积的减少可分别达到1.0g/dL和3.3%)。此"}, {"probability": {"variance": 0.012284, "average": 0.969458, "min": 0.407706}, "location": {"width": 830, "top": 1179, "height": 43, "left": 192}, "words": "改变主要出现于服药开始的4—8周,而后相对保持恒定。服用罗格列患者可见轻度白细"}, {"probability": {"variance": 0.006574, "average": 0.974058, "min": 0.536147}, "location": {"width": 821, "top": 1205, "height": 45, "left": 192}, "words": "胞计数减少。上述改变可能与血容量增加有关,无临床意义《详见不良反应实验室异常章节)"}, {"probability": {"variance": 0.008368, "average": 0.968821, "min": 0.503767}, "location": {"width": 787, "top": 1233, "height": 43, "left": 239}, "words": "水肿:水肿患者应慎用本品。在健康志愿者参加的临床试验中,受试者服用罗格列酮8"}, {"probability": {"variance": 0.00013, "average": 0.993192, "min": 0.950591}, "location": {"width": 829, "top": 1263, "height": 42, "left": 192}, "words": "毫克/日,一日一次,连续服用8周,结果表明,与安慰剂组相比,给药组平均血容量增加"}, {"probability": {"variance": 0.00093, "average": 0.989368, "min": 0.872197}, "location": {"width": 262, "top": 1300, "height": 27, "left": 233}, "words": "8ml/kg),且具有统计学意义"}, {"probability": {"variance": 4e-05, "average": 0.997136, "min": 0.962411}, "location": {"width": 791, "top": 1314, "height": 46, "left": 230}, "words": "2型糖尿病患者参加的对照临床试验中,有出现轻至中度水肿的报道(详见不良反应章"}, {"probability": {"variance": 4.3e-05, "average": 0.993134, "min": 0.986596}, "location": {"width": 30, "top": 1362, "height": 22, "left": 196}, "words": "节)"}, {"probability": {"variance": 0.007057, "average": 0.971624, "min": 0.615461}, "location": {"width": 788, "top": 1371, "height": 43, "left": 233}, "words": "鉴于噻唑烧二削类药物引起体液潴留,有加重充血性心衰的危险,对有心衰危险的患者"}, {"probability": {"variance": 0.021417, "average": 0.932917, "min": 0.355377}, "location": {"width": 750, "top": 1400, "height": 42, "left": 214}, "words": "龙其是合用胰岛素治疗者)应严密监测其心衰的症状和体征(见心功能全部分)"}, {"probability": {"variance": 0.01296, "average": 0.960081, "min": 0.53407}, "location": {"width": 787, "top": 1429, "height": 41, "left": 235}, "words": "心功能不全:临床前研究表明噻烷二类药物(包括本品)可引起血容增加,以及"}, {"probability": {"variance": 0.001156, "average": 0.987536, "min": 0.808266}, "location": {"width": 824, "top": 1454, "height": 44, "left": 197}, "words": "由于前负荷增加所致的心脏肥大,两项超声心动图研究,以评估罗格列酮对2型糖尿病患者"}, {"probability": {"variance": 4.7e-05, "average": 0.997341, "min": 0.956092}, "location": {"width": 829, "top": 1480, "height": 47, "left": 196}, "words": "心脏的影响,结果表明患者无心脏结构各功能的异常改变。其中一项试验为服用罗格列酮4"}, {"probability": {"variance": 0.011486, "average": 0.961887, "min": 0.560305}, "location": {"width": 806, "top": 1512, "height": 41, "left": 196}, "words": "毫克/次,每日2次,连续服用52周(共86人),另一项试验为服用罗格列酮8毫克/日"}], "language": 3}